

27 September 2023

ASX ANNOUNCEMENT

ImpediMed Announces Appointment of Chief Medical Officer

ImpediMed Limited (ASX:IPD) is pleased to announce the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023.

Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry.

Dr. Chen's previous leadership and experience:

- Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care.
- Chief of Breast Surgery, University of California Davis Medical Center.
- Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California.
- Past President, American Society of Breast Surgeons (ASBrS).
- Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics.
- Over 70 publications and 5,000 citations (<https://bit.ly/schenbiblio>).

The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®).

Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons.

Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business.

"As a practicing breast surgeon and past president of ASBrS, I have firsthand experience with lymphoedema and understand the benefit of preventing lymphoedema to improve quality of life for breast cancer patients. With the recent milestones of NCCN Guidelines® and growing reimbursement coverage, this is an exciting time to join ImpediMed and I am excited to help further drive bioimpedance spectroscopy technology as standard of care for cancer patients," stated Dr. Chen.

Commenting on the appointment, Rick Valencia, ImpediMed's Managing Director and CEO said, "We are honored and excited to have such an experienced and credentialed leader join us as Chief Medical Officer.

Dr. Chen will be instrumental in charting our growth strategy in cancer-related lymphedema, new indications for oncology, and expansion into other specialty areas.”

Approved for release by the Managing Director & CEO, Richard Valencia.

Contact Details

Investor Relations Contact:

Hannah Howlett

WE Communications

T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.